Investors
Company Profile
OROCIDIN is a development company with an ambition to develop the preferred treatment against aggressive periodontitis. Upon successfully demonstrating the project’s feasibility in treating periodontitis and securing worldwide IP rights, OROCIDIN will proceed with its projected sale of the project. The anticipated timeline for advancing the development project for periodontitis and establish the global IP rights is approx. 30 months, starting in October 2023.
Governance
The governance policies at OROCIDIN provides the company with a comprehensive structure ensuring practices to meet all legal and regulatory requirements. We further strive to implement good corporate governance to all stakeholders. Operations within OROCIDIN are conducted with utmost financial integrity, all decisions are taken in the best interests of the shareholders both for the minority and majority shareholders. Questions etc. can be assessed through our email info@orocidin.com
Financial reports
The first financial year ends 31. March 2025.